The primary challenge of MDR becoming a treatment for HCC lies in the overexpression of the ATP-binding cassette (ABC) transporter family in cancer cells, including ABCG1, ABCC1, and ABCG2 [44, 45]. This evidence concerns the gene ABCG2 and hepatocellular carcinoma.